PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-2.60%
Cash & equivalents declining -2.60% while TRVN's grows 70.84%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-2.60%
Cash + STI yoy 0.5-0.75x TRVN's -5.13%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.51%
Other current assets growth < half of TRVN's 30.74%. David Dodd sees a leaner approach to short-term items.
-2.19%
0.5-0.75x TRVN's -3.60%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-4.69%
1.25-1.5x TRVN's -3.55%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.67%
Below half of TRVN's -23.35%. Michael Burry sees possible underinvestment in long-term assets. Verify capital constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
Below half of TRVN's -9.52%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Below half of TRVN's -4.58%. Michael Burry sees a potential red flag for stagnation or capital shortage.
28.73%
Less than half of TRVN's 67.51%. David Dodd sees a more disciplined AP approach or lower volume.
27.69%
Less than half of TRVN's 416.67%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
38361.54%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
-27.69%
Higher Other Current Liabilities Growth compared to TRVN's zero value, indicating worse performance.
27.28%
Less than half of TRVN's -5.67%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Less than half of TRVN's 22.36%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.72%
Less than half of TRVN's 13.46%. David Dodd sees far fewer liability expansions relative to competitor.
4.00%
Less than half of TRVN's -95.38%. David Dodd sees fewer share issuances vs. competitor.
-3.83%
≥ 1.5x TRVN's -1.30%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.70%
Below half TRVN's -28.65%. Michael Burry sees potential underperformance in building shareholder capital.
-2.25%
Below half TRVN's -4.58%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.67%
Below half TRVN's -89.09%. Michael Burry suspects major underinvestment or forced divestment.
-0.77%
Less than half of TRVN's -1.56%. David Dodd sees less overall debt expansion vs. competitor.
2.64%
Less than half of TRVN's -688.57%. David Dodd sees better deleveraging or stronger cash buildup than competitor.